The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Association between disease control and PRO improvement: A post hoc analysis of BE OPTIMAL and BE COMPLETE
|
Increasing patient HR-QoL is a key goal in the treatment of PsA.1 However, it is currently not known whether common measures of clinical efficacy can associated with changes in PROs in patients with PsA. A post hoc analysis of the BE OPTIMAL and BE COMPLETE trials investigated the association between achieving stringent clinical disease control and improvements in PROs. In these trials, patients with PsA who were bDMARD-naïve or TNFi-IR were treated with bimekizumab for 52 (BE OPTIMAL) or 40 weeks (BE COMPLETE). Results from the post hoc analysis were published in Therapeutic Advances in Musculoskeletal Disease by Kristensen et al.1
|
| Key learnings |
| Improvements in PROs were sustained over time, from Week 16 through Week 52/40, reinforcing the long-term efficacy and impact of bimekizumab treatment. |
| Achievement of stringent clinical disease control criteria, including ACR70, DAPSA, LDA/REM, and MDA, correlated with greater improvements in PROs. For example, 94.7% of patients who were bDMARD-naïve and 97.6% who were TNFi-IR and achieved ACR70 also reported a ≥50% pain reduction after 52 and 40 weeks of bimekizumab treatment. |
| Addressing skin involvement (PASI 100) further reduced patient-perceived disease impact of the skin; patients who achieved PASI 100 had greater reductions in PsAID-12 skin problem single item domain score at Week 52/40 vs those who did not. |
| These findings highlight the importance of achieving and maintaining stringent disease control with PsA treatment to attain optimal PRO improvements. Bimekizumab’s efficacy supports its role as a therapeutic option in PsA management, particularly for achieving increased HR-QoL. |
Abbreviations: ACR70, 70% improvement in American College of Rheumatology response; bDMARD, biologic disease-modifying antirheumatic drug; DAPSA; Disease Activity Index for Psoriatic Arthritis; HR-QoL, health-related quality of life; LDA, low disease activity; MDA, Minimal Disease Activity; PASI, Psoriasis Area and Severity Index; PRO, patient-reported outcome; PsA, psoriatic arthritis; PsAID-12, 12-item PsA Impact of Disease; REM, remission; TNFi-IR, inadequate response or intolerance to tumor necrosis factor inhibitor.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
